Drugs News and Research

RSS

Results of darexaban phase II trial in recent acute coronary syndrome presented at ESC Congress

A phase II dose-finding study has found that the new oral Factor Xa inhibitor darexaban was associated with a two to four-fold increase in bleeding when added to dual antiplatelet therapy in patients following an acute coronary syndrome.

30 Aug 2011

An advance toward using stem cells in 'regenerative medicine'

With stem cells so fickle and indecisive that they make Shakespeare's Hamlet pale by comparison, scientists today described an advance in encouraging stem cells to make decisions about their fate.

30 Aug 2011

Everolimus-eluting stent reduces incidence of stent thrombosis

Results of the independently-funded Bern-Rotterdam cohort study provide robust evidence of an "important" reduction in overall and very late stent thrombosis.

30 Aug 2011

Ipsen, Inspiration partner to launch hemophilia product portfolio in Europe

Ipsen and Inspiration Biopharmaceuticals Inc. today announced they have entered into a strategic partnership agreement, to create a European hemophilia commercial organization, to launch Inspiration's hemophilia product portfolio in Europe.

30 Aug 2011

New chemical compounds show promise against set of protein-folding diseases

Collaborating researchers at Stanford University and The Scripps Research Institute have identified chemical compounds that show promise as potential therapeutics for a set of medical conditions caused by the abnormal clumping together of a protein known as transthyretin.

30 Aug 2011

Study indicates large gap in use of proven therapies for heart attack or stroke

A global study in 17 countries led by McMaster University researchers has found too few patients are using drugs proven to give significant benefits in warding off a heart attack or stroke.

30 Aug 2011

Bristol Meyer Squibb’s new blood thinner drug for stroke prevention

Researchers find that an experimental anticlotting pill Eliquis is more effective than standard drug, warfarin, at preventing strokes in people with a heart condition that puts them at high risk of blood clots and stroke. The new drug also known as apixaban, cut the risk of stroke by 21% compared with warfarin in people with atrial fibrillation (AF). It lowered the risk of dying by 11%.

30 Aug 2011

Governor Perry attacked for choosing new medical treatment

Recently, the governor of Texas and presidential hopeful had a bad back treated by injecting some of his very own fat cells, after they had been cultured and treated in a laboratory. The innovative use of a patient’s own adult stem cells is showing great promise in many conditions, including damaged joints.

29 Aug 2011

Curemark's novel compound CM-182 shows promise for treatment of hyperactivity without sedation

Curemark, LLC, a drug research and development company focused on the treatment of neurological diseases, announced today that its compound CM-182 demonstrated positive results for reduction in hyperactivity in mice treated with amphetamines. The mouse model screening was performed by the contract research organization, Cerca Insights.

29 Aug 2011

Infrared Systems completes several internal projects, discusses corporate strategies

Infrared Systems International announces the completion of several internal projects and discusses corporate strategies for continued success.

29 Aug 2011

FDA acts to prevent distribution of food from rodent-infested facility

At the request of the U.S. Food and Drug Administration, U.S. Marshals seized all FDA-regulated food susceptible to rodent and pest contamination or other filth held at the Durham, North Carolina, warehouse of CFSD, Inc., which does business as Chan's Food Service.

29 Aug 2011

Statins protect people against death from respiratory illness, infections

The death rate among patients prescribed a statin in a major trial that ended in 2003 is still lower than those given a placebo, even though most participants in both groups have been taking statins ever since. ASCOT, the Anglo-Scandinavian Cardiac Outcomes Trial, was stopped early because the statin was so effective at preventing heart attacks and strokes, but a new analysis has shown that eight years on, the most significant difference between the groups is a reduction in deaths from infection and respiratory illness.

29 Aug 2011

Sutureless method for reconnecting blood vessels

Reconnecting severed blood vessels is mostly done the same way today - with sutures - as it was 100 years ago, when the French surgeon Alexis Carrel won a Nobel Prize for advancing the technique.

29 Aug 2011

People with lower socioeconomic status more likely to develop heart disease

People with lower socioeconomic status are much more likely to develop heart disease than those who are wealthier or better educated, according to a recent UC Davis study.

29 Aug 2011

Pfizer's Xalkori receives FDA approval to treat late-stage NSCLC patients with abnormal ALK gene

The U.S. Food and Drug Administration today approved Xalkori (crizotinib) to treat certain patients with late-stage (locally advanced or metastatic), non-small cell lung cancers (NSCLC) who express the abnormal anaplastic lymphoma kinase (ALK) gene.

29 Aug 2011

LUNGevity Foundation applauds FDA's recent approval of XALKORI lung cancer drug

LUNGevity Foundation applauds the US Food and Drug Administration's (FDA) recent approval of XALKORI (crizotinib) to treat lung cancer. The drug, introduced by Pfizer, Inc. showed such promise in early trials that it was given "fast track" status by the FDA.

29 Aug 2011